title: Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial.
abstract: BACKGROUND
  Sodium valproate (SV) has been approved for migraine prophylaxis and its intravenous form is used to treat acute migraine attacks. We compared the efficacy and safety of intravenous SV and subcutaneous Sumatriptan in managing acute migraine attacks.
  
  
  METHODS
  This double-blind randomized clinical trial divided 90 patients into two groups: one group received 400 mg of intravenous SV and the second group received 6 mg of subcutaneous Sumatriptan. Headache severity before treatment and half an hour, one hour, and two hours after treatment was measured based on the VNRS in the groups. Associated symptoms, i.e., photophobia, phonophobia, nausea, and vomiting, were assayed on admission and 2 hours after treatment. Side effects of the drugs were checked 2 hours after injection. Obtained data from the groups were compared.
  
  
  RESULTS
  In both groups, pain decrement at the mentioned time points was significant (P<0.001), but had no significant difference (P>0.05), indicating the similar effect of both drugs on pain improvement. In the SV group, photophobia, phonophobia, nausea, and vomiting were improved significantly, while in the Sumatriptan group, only photophobia and vomiting were decreased significantly, indicating the advantage of SV in improving the associated symptoms. Nausea, vomiting, facial paresthesia, and hypotension were more significantly frequent in the Sumatriptan group than in the SV group (P<0.05).
  
  
  CONCLUSIONS
  Intravenous SV (400 mg) was as effective as subcutaneous Sumatriptan in the treatment of acute migraine attacks, but with more improvement in associated symptoms and with fewer side effects.
  
  
  BACKGROUND
  IRCT201108025943N4.
authors.affiliation: Department of Neurology, Yazd University of Medical Science, Yazd, Iran.
authors.forename: Abolghasem
authors.initials: A
authors.lastname: Rahimdel
authors.affiliation: Department of Neurology, Yazd University of Medical Science, Yazd, Iran.
authors.forename: Ali
authors.initials: A
authors.lastname: Mellat
authors.affiliation: Department of Neurology, Yazd University of Medical Science, Yazd, Iran.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Zeinali
authors.affiliation: Department of Neurology, Yazd University of Medical Science, Yazd, Iran.
authors.forename: Elahe
authors.initials: E
authors.lastname: Jafari
authors.affiliation: Department of Neurology, Yazd University of Medical Science, Yazd, Iran.
authors.forename: Parisa
authors.initials: P
authors.lastname: Ayatollahi
keywords: Migraine; Sodium valproate; Sumatriptan
references.citation: Expert Opin Pharmacother. 2012 Nov;13(16):2369-80
references.pmid: 23013035
references.citation: N Engl J Med. 2005 Mar 17;352(11):1112-20
references.pmid: 15784664
references.citation: Handb Exp Pharmacol. 2007;(177):129-43
references.pmid: 17087122
references.citation: Rev Neurol. 2012 Jun 1;54(11):641-8
references.pmid: 22627745
references.citation: Rev Neurol. 2012 May 16;54(10):629-37
references.pmid: 22573510
references.citation: CNS Drugs. 2002;16(10):669-94
references.pmid: 12269861
references.citation: Int J Neurosci. 2012 Feb;122(2):60-8
references.pmid: 21950578
references.citation: J Clin Psychopharmacol. 2005 Aug;25(4):376-80
references.pmid: 16012283
references.citation: Med J Aust. 2008 Sep 1;189(5):283-8
references.pmid: 18759728
references.citation: Neurology. 2008 Nov 25;71(22):1821-8
references.pmid: 19029522
references.citation: Cephalalgia. 2002 Oct;22(8):633-58
references.pmid: 12383060
references.citation: Neuro Endocrinol Lett. 2007 Feb;28(1):59-64
references.pmid: 17277725
references.citation: Cephalalgia. 2006 Sep;26(9):1051-60
references.pmid: 16919055
references.citation: Neurology. 2012 Apr 24;78(17):1337-45
references.pmid: 22529202
references.citation: Nervenarzt. 2012 Dec;83(12):1600-8
references.pmid: 23180057
references.citation: Headache. 2001 Nov-Dec;41(10):976-80
references.pmid: 11903525
references.citation: Headache. 2000 Oct;40(9):720-3
references.pmid: 11091289
references.citation: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD009665
references.pmid: 22336869
references.citation: Neurol Sci. 2012 May;33 Suppl 1:S37-41
references.pmid: 22644168
references.citation: Headache. 2013 Jan;53(1):168-176
references.pmid: 23293866
references.citation: Neurology. 2000 Sep 26;55(6):754-62
references.pmid: 10993991
references.citation: Acta Neurol Scand. 2011 Apr;123(4):257-65
references.pmid: 20569223
references.citation: Neurology. 2007 Jan 30;68(5):343-9
references.pmid: 17261680
references.citation: Acta Neurol Scand. 1988 Oct;78(4):346-8
references.pmid: 3146862
references.citation: Lancet. 2004 Jan 31;363(9406):381-91
references.pmid: 15070571
references.citation: Headache. 2005 Jan;45(1):42-6
references.pmid: 15663612
references.citation: Cephalalgia. 2010 Sep;30(9):1065-72
references.pmid: 20713557
references.citation: Ann Intern Med. 2002 Nov 19;137(10):840-9
references.pmid: 12435222
references.citation: Neuropediatrics. 2013 Feb;44(1):40-5
references.pmid: 23299655
references.citation: CNS Drugs. 2002;16(6):385-403
references.pmid: 12027785